NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Petco and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class act ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Rocket Pharmaceuticals and its officers or directors [1] Group 1: Company Developments - On May 27, 2025, Rocket Pharmaceuticals announced an update regarding its investigational gene therapy RP-A501 for Danon disease, revealing that a patient in the Phase 2 trial experienced a Serious Adverse Event (SAE) related to capillary leak syndrome [3] - Following the SAE, Rocket paused further dosing in the study, and the FDA placed a clinical hold on the trial for further evaluation [3] - The patient involved in the SAE subsequently passed away due to an acute systemic infection [3] - As a result of this news, Rocket's stock price dropped by $3.94 per share, or 62.84%, closing at $2.33 per share on May 27, 2025 [3] Group 2: Legal and Investigative Actions - Pomerantz LLP is reaching out to investors of Rocket Pharmaceuticals to investigate claims of potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

BENSALEM, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEOGEN CORPORATION (NEOG), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by ...

Company Overview - EchoStar Corporation, along with its subsidiaries, provides networking technologies and services [3] Recent Developments - On May 12, 2025, The Wall Street Journal reported that the Federal Communications Commission (FCC) would investigate EchoStar's compliance with federal requirements for building a nationwide 5G network, leading to a stock price drop of over 16% [4] - On May 30, 2025, EchoStar announced it would not make a cash interest payment of approximately $326 million to allow time for the FCC to provide requested relief, resulting in an additional 12% decline in stock price [5] - On June 2, 2025, EchoStar disclosed it would similarly not make approximately $183 million in cash interest payments due to uncertainty from the FCC review, causing a further stock price drop of more than 11% [6] Legal Investigation - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving EchoStar, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Rocket Pharmaceuticals and its officers or directors following a serious adverse event in a clinical trial that led to a significant drop in the company's stock price [1][3]. Group 1: Company Developments - On May 27, 2025, Rocket Pharmaceuticals announced an unexpected serious adverse event (SAE) related to its investigational gene therapy RP-A501 for Danon disease, which involved clinical complications from capillary leak syndrome [3]. - Following the SAE, Rocket voluntarily paused further dosing in the Phase 2 pivotal trial, and the FDA placed a clinical hold on the trial for further evaluation [3]. - The patient involved in the SAE subsequently passed away due to an acute systemic infection [3]. Group 2: Market Reaction - The announcement of the SAE resulted in Rocket's stock price falling by $3.94 per share, a decrease of 62.84%, closing at $2.33 per share on May 27, 2025 [3]. Group 3: Legal Context - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is representing investors in the investigation regarding Rocket Pharmaceuticals [1][4].

Group 1 - Savara Inc. shares fell over 30% in intraday trading on May 27, 2025, following the FDA's issuance of a Refusal to File letter for its Biologics License Application for Molbreevi, its lead drug candidate for autoimmune PAP [2] - The FDA cited that the submission was "not sufficiently complete" for review, specifically pointing out issues with the CMC section of the application, and Savara was unable to specify what data was missing or why deficiencies were not addressed prior to submission [2] Group 2 - Block & Leviton is investigating Savara Inc. for potential securities law violations and may file an action to recover losses for investors [4] - Investors who have lost money in Savara Inc. investments are encouraged to contact Block & Leviton to learn more about recovery options [5][3] Group 3 - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors and representing many top institutional investors [7]

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices involving Methanex Corporation and its officers or directors [1]. Group 1: Company Performance and Events - On March 9, 2025, Methanex announced an unplanned outage at its 1.8 million tonne methanol plant, Geismar 3, in Louisiana, which occurred in late February [3]. - Following the outage announcement, Methanex's management decided to repair the autothermal reformer (ATR) and estimated a plant startup by early May 2025 [3]. - The stock price of Methanex fell by $5.45 per share, or 12.9%, closing at $36.80 per share on March 10, 2025, after the announcement [4]. Group 2: Legal and Regulatory Context - Pomerantz LLP, a firm known for its work in corporate, securities, and antitrust class litigation, is leading the investigation into Methanex [5]. - The firm has a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [5].